Abstract 4631: Evaluation of the impact of homozygous MTAP truncations on the activity and selectivity of MTA-cooperative PRMT5 inhibitorsMatthew R. Tonini, Kimberly J. Briggs, André A. Mignault et al.|Cancer Research|2024Cited by 1
Tumor suppressor collateral damage screens reveal mRNA homeostasis protein HBS1L as a novel vulnerability in ch9p21 driven FOCAD deleted cancerHongxiang Zhang, Teng Teng, Hannah Stowe et al.|Biochimica et Biophysica Acta (BBA) - Molecular Cell Research|2025Cited by 1
Abstract B098: Unbiased in vitro and in vivo drug anchor screens identify mechanisms of resistance and sensitization for MTA-cooperative PRMT5 inhibitors in MTAP-deleted cancer modelsSteven Lombardo, Teng Teng, Matthew R. Tonini et al.|Molecular Cancer Therapeutics|2023Cited by 0
Tumor suppressor collateral damage screens reveal mRNA homeostasis protein HBS1L as a novel vulnerability in ch9p21 driven FOCAD deleted cancerHongxiang Zhang, Teng Teng, Matthew R. Tonini et al.|bioRxiv (Cold Spring Harbor Laboratory)|2025Cited by 0
Abstract 4608: Evaluation of the impact of homozygous MTAP truncations on the clinical activity of MTA-cooperative PRMT5 inhibitorsKimberly J. Briggs, Adam Crystal, Andre Mignault et al.|Cancer Research|2025Cited by 0